upcoming Licensing and new technologies

pre-clinical stage

Astheneia Bio is negotiating a licensing agreement for a first in class and first line HPV+ and associated tumors immunotherapy with an estimated IND filing mid-2026.

Literature

in-vivo GBM mouse modelS using CAR-Neutrophil dual-immunotherapy

disclosures and disclaimers

The website contains forward looking statements about the scientific expectations of the data gathered to date. We expressly disclaim any obligation to update any forward-looking statement in the event it later turns out to be inaccurate, whether as a result of new information, future events or otherwise.